Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Dalpiciclib + Chemotherapy in Neoadjuvant LA-HNSCC
NCT07778732Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 2 trial of adebrelimab, dalpiciclib in head and neck squamous cell carcinoma (HNSCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
adebrelimabdalpiciclib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07778732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778732.